ISSN 2149-2263 | E-ISSN 2149-2271
The Anatolian Journal of Cardiology
Hypertension and valsartan [Anatol J Cardiol]
Anatol J Cardiol. 2014; 14(Suppl 2): 20-24 | DOI: 10.5152/akd.2014.00004

Hypertension and valsartan

Pınar Kızılırmak1, Ali Yağız Üresin1
Department of Medical Pharmacology, İstanbul Faculty of Medicine, İstanbul University; İstanbul-Turkey

Hypertension, which is pointed to be the most frequent cause of death in the World and in Turkey and defined by the World Health Organization as global health crisis and the prominent risk factor for cardiovascular diseases, is a problem threatening public health. Renin-angiotensin system (RAS) plays an important role in pathophysiology and in turn treatment of the disease. The drugs suppressing RAS are recommended both for monotherapy and combinations. Together with the blood pressure lowering effects and positive contributions of this group of drugs to the cardiovascular and renal process have been proved by clinical studies. In this review, the recent developments about the hypertension treatment were summarized and the place of valsartan molecule, being an angiotensin receptor blocker in hypertension treatment, was examined in the light of the studies in which the effectiveness, tolerability and safety of valsartan were evaluated.

Keywords: hypertension, angiotensin receptor blockers, valsartan

Pınar Kızılırmak, Ali Yağız Üresin. Hypertension and valsartan. Anatol J Cardiol. 2014; 14(Suppl 2): 20-24
Manuscript Language: English

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 The Anatolian Journal of Cardiology

Kare Publishing is a subsidiary of Kare Media.